Company Profile
Nektar Therapeutics Stock Price, News & Analysis
- Ticker:
- NKTR
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Nektar Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
66.69 USD (+1.51%)
Close
Last updated: June 23, 2026 at 00:00
2.25B USD
Market cap
Why the stock is moving
NKTR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Nektar Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Nektar Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Nektar Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Source: Nektar Therapeutics
- 02
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Source: Nektar Therapeutics
- 03
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Source: Nektar Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nektar Therapeutics (NKTR)?
Nektar Therapeutics (NKTR) most recently closed at 66.69 USD, a +1.51% move versus the previous session.
What is the market cap of Nektar Therapeutics (NKTR)?
Nektar Therapeutics currently has a market capitalization of 2.25B USD on BioPharmSignal.
What does Nektar Therapeutics do?
Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is NKTR stock listed?
Nektar Therapeutics (NKTR) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Nektar Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Nektar?
Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Nektar Therapeutics targeting with Nektar?
Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.